PubRank

David Khayat

Author PubWeight™ 96.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 30.26
2 Delivering affordable cancer care in high-income countries. Lancet Oncol 2011 12.79
3 In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc 2015 4.70
4 Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009 3.69
5 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013 2.39
6 Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002 1.78
7 Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006 1.51
8 VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2009 1.45
9 Quality trials and quality of life in non-small-cell lung cancer. J Clin Oncol 2003 1.41
10 Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int 2013 1.40
11 Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2009 1.32
12 Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005 1.32
13 Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010 1.31
14 AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008 1.28
15 Metastatic melanoma: chemotherapy. Semin Oncol 2002 1.20
16 Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 2011 1.18
17 Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol 2009 1.04
18 Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009 1.02
19 Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol 2010 0.97
20 Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer 2012 0.96
21 Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol 2002 0.96
22 Lung cancer in patients with HIV Infection and review of the literature. Med Oncol 2004 0.96
23 Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002 0.96
24 Malignant melanoma. Crit Rev Oncol Hematol 2003 0.94
25 Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 2007 0.92
26 Bevacizumab treatment for advanced breast cancer. Oncologist 2011 0.90
27 Paving the way to the cure of melanoma. Melanoma Res 2010 0.90
28 Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol 2008 0.89
29 Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005 0.88
30 Retracted Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. J Clin Oncol 2011 0.87
31 Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer 2011 0.87
32 Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 2002 0.86
33 Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 2005 0.85
34 Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol 2010 0.84
35 Tobacco: deadly in any form or disguise. Lancet 2006 0.83
36 A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Clin Lung Cancer 2013 0.83
37 Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study. PLoS One 2012 0.81
38 Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 2004 0.81
39 Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions. Oncologist 2008 0.81
40 Cetuximab plus irinotecan in refractory colorectal cancer patients. Expert Rev Anticancer Ther 2007 0.79
41 Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer. Clin Cancer Res 2004 0.79
42 Quality of life: it's never too late. J Clin Oncol 2002 0.79
43 Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 2009 0.78
44 Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. Epigenetics 2015 0.78
45 An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res 2006 0.78
46 [Neoadjuvant endocrine therapy for breast cancer: an overview]. Bull Cancer 2004 0.77
47 Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res 2010 0.77
48 Temsirolimus-induced glomerulopathy. Oncology 2009 0.77
49 Atypical Presentation of Hepatocellular Carcinoma Mimicking a Gastric Hepatoid Adenocarcinoma: A Case Report. Medicine (Baltimore) 2015 0.77
50 Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Bull Cancer 2005 0.77
51 Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol 2004 0.76
52 A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy. J Clin Oncol 2009 0.75
53 [Geriatric oncology: epidemiological evidence]. Presse Med 2009 0.75
54 Are we entering a new era in melanoma treatment? Lesson from ASCO 2011. Melanoma Res 2011 0.75
55 [Anemia in cancer patients before treatment]. Bull Cancer 2003 0.75
56 [Aromatase inhibitors in adjuvant setting in breast cancer]. Bull Cancer 2004 0.75
57 Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet 2005 0.75
58 Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer 2011 0.75